Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/8953
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAdakudugu, Emmanuel A.-
dc.contributor.authorAmeyaw, Elvis Ofori-
dc.contributor.authorObese, Ernest-
dc.contributor.authorBiney, Robert Peter-
dc.contributor.authorHenneh, Isaac Tabiri-
dc.contributor.authorAidoo, Douglas B.-
dc.contributor.authorOge, Elizabeth N.-
dc.contributor.authorAttah, Isaac Y.-
dc.contributor.authorObiri, David D.-
dc.date.accessioned2023-10-03T16:44:19Z-
dc.date.available2023-10-03T16:44:19Z-
dc.date.issued2020-
dc.identifier.urihttp://hdl.handle.net/123456789/8953-
dc.description.abstractBergapten (5-methoxysporalen) is a furanocoumarin extracted from several species of citrus and bergamot oil. Bergamot essential oil is used traditionally in the management of inflammatory conditions. Previous studies on bergapten have explored mainly its in vitro anti-inflammatory activities which include suppression of the expression and release of pro-inflammatory cytokines such as TNF-α and interleukins as well as prostaglandins. Bergapten enhances the clearance of neutrophils and macrophages from the site of inflammation and reduces oxidative stress by inhibition of reactive oxygen species (ROS). Bergapten was assessed for its anti-inflammatory properties in acetic acid-induced colitis. Animals were obtained and randomly placed in six (6) groups (n ¼ 5) after acclimatization. Colitis was induced by rectal administration using 4% v/v acetic acid in Sprague Dawley rats after pre-treatment for 5 days. Bergapten was administered at doses of 3, 10, and 30 mg kg 1 p.o. while the control group received saline 5 mL kg 1 p.o. and the standard drug employed was sulphasalazine at a dose of 500 mg kg 1. Assessments made for colon-weight-to-length ratio, colonic injury, and mucosal mast cell degranulation. There were reduced colon-weight-to-length ratios in animals treated with bergapten which was significant (p < 0.5) for doses 10 and 30 mg kg 1 compared to the disease control group Both macroscopic and microscopic damage were reduced as well, with a lesser percentage of degranulated mast cells. Macroscopic damage was reduced for bergapten at doses 10 and 30 mg kg 1 significantly at p < 0.5 and p < 0.001, respectively. Similarly, microscopic damage was reduced at p < 0.01 and p < 0.001 respectively for bergapten 10 and 30 mg kg 1. The reduction of degranulation by bergapten was significant at p < 0.001. There was generally reduced damage at inflammatory sites as well as decreased infiltration of inflammatory cells. Overall, bergapten reduces inflam- mation in acetic acid-induced colitis.en_US
dc.language.isoenen_US
dc.publisherCell Pressen_US
dc.subjectPharmaceutical scienceen_US
dc.subjectImmunologyen_US
dc.subjectPathologyen_US
dc.subjectPhysiologyen_US
dc.subjectBergaptenen_US
dc.subjectUlcerative colitisen_US
dc.subjectMast cellsen_US
dc.subjectimmune modulatorsen_US
dc.subjectBiological sciencesen_US
dc.subjectHealth sciencesen_US
dc.subjectGastrointestinal systemen_US
dc.subjectPharmacology Evidence-based medicineen_US
dc.titleProtective effect of bergapten in acetic acid-induced colitis in ratsen_US
dc.typeArticleen_US
Appears in Collections:School of Allied Health Sciences

Files in This Item:
File Description SizeFormat 
Protective effect of bergapten in acetic acid-induced colitis in rats.pdfMain article1.08 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.